Johnson & Johnson Vision announced that it has completed its acquisition of TearScience. Terms of the deal were not disclosed. The move expands Johnson & Johnson's eye health portfolio and its presence in the growing dry eye disease treatment market.
In 2012, TearScience launched its in-office "Dry Eye Solution," which included the LipiView, the first device of its kind that captures images of meibomian glands in the eyelids, and the LipiFlow Thermal Pulsation System, which treats evaporative dry eye by liquefying and evacuating obstructions in meibomian glands. In 2014, TearScience introduced the LipiView II, which employed reflected and transilluminated light sources to provide high definition structural meibomian gland images. In 2016, TearScience announced the release of LipiScan, the first dedicated high-definition gland imager that allows eye care professionals to assess meibomian gland structure during routine workups in a practice setting.
"TearSciene is in a growing space and we think it's a differentiated technology," Ashley McEvoy, Company Group Chairman, responsible for the Johnson & Johnson Vision Companies, said in an interview with Eyewiretoday.com after the acquisition was announced in August. "It's one of the only fully FDA-approved systems. And what we really love about it is it’s a mechanical solution to a mechanical problem."
Dry eye impacts an estimated 340 million people globally, and MGD, a chronic, progressive condition that can range from mild to severe pain, is the leading cause. Patients with MGD may present in an optometrist’s office or at an ophthalmology appointment, so the disease is treated across the eye care community. TearScience technologies allow physicians to evaluate meibomian gland health and treat MGD with a 12-minute in-office treatment.
Johnson & Johnson Vision acquired TearScience through its surgical vision operating company, Abbott Medical Optics. Sales will be reported in the Medical Devices segment, under Vision Care.